Arcadia Biosciences, Inc. (RKDA) — Financial statements
Income statement, balance sheet, and cash flow for Arcadia Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 5↓3.7% | 5↑13.3% | 4↓40.0% | 7↑9.4% | 7 | |
| Cost of Revenue | 3↑4.6% | 3↑36.3% | 2↓64.4% | 6↓29.9% | 9 | |
| Gross Profit | 2↓15.5% | 2↓8.7% | 2↑73.1% | 1↑168.3% | -2 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.01↓83.0% | 0.05↓17.2% | 0.06↓95.8% | 2↓61.2% | 4 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 12↑21.8% | 10↑17.1% | 8↓45.2% | 15↓34.4% | 23 | |
| Other Expenses | 0.00↑100.0% | -4↓4819.0% | 0.08↑106.9% | -1↓118.0% | 7 | |
| Operating Expenses | 12↑105.1% | 6↓31.6% | 8↓45.3% | 15↓54.4% | 34 | |
| Total Costs & Expenses | 15↑70.9% | 9↓17.6% | 11↓50.7% | 21↓49.4% | 42 | |
| Operating Results | ||||||
| Operating Income | -10↓174.0% | -4↑40.2% | -6↑56.4% | -14↑60.6% | -36 | |
| Depreciation & Amortization | 0.15↑36.3% | 0.11↓60.6% | 0.29↓40.1% | 0.48↓54.2% | 1 | |
| EBITDA | -10↓31.2% | -7↓30.8% | -6↑61.1% | -15↑46.8% | -28 | |
| EBIT | -10↓31.3% | -8↓26.5% | -6↑60.5% | -15↑47.0% | -29 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.22↓71.7% | 0.78↑12.5% | 0.70↑140.5% | 0.29↑1545.0% | -0.02 | |
| Interest Income | 0.22↓71.7% | 0.78↑12.5% | 0.70↑140.5% | 0.29 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.02 | |
| Non-Operating Income | 0.00↓100.0% | 4↑4819.0% | -0.08↓106.9% | 1↑118.0% | -7 | |
| Other Income / Expenses | 8↑1259.5% | -0.66↓184.6% | 0.78↓75.5% | 3↓83.5% | 19 | |
| Income Before Tax | -2↑45.9% | -4↑19.0% | -5↑50.8% | -11↑33.0% | -16 | |
| Income Tax Expense | 0.01↑0.0% | 0.01↑0.0% | 0.01↓42.9% | 0.01↑600.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -2↑45.8% | -4↑19.0% | -5↑50.8% | -11↑32.9% | -16 | |
| Net Income from Discontinued Operations | 0.00↑100.0% | -3↑68.6% | -9↓81.0% | -5 | 0.00 | |
| Net Income | -2↑66.8% | -7↑49.7% | -14↑9.1% | -15↓4.9% | -15 | |
| Bottom-Line Net Income | -2↑66.8% | -7↑49.7% | -14↑9.1% | -15↓4.9% | -15 | |
| EPS (Basic) | -1.71↑66.9% | -5.16↑54.3% | -11.30↑56.6% | -26.05↑14.1% | -30.33 | |
| EPS (Diluted) | -1.71↑66.9% | -5.16↑54.3% | -11.30↑56.6% | -26.05↑14.1% | -30.33 | |
| Weighted Average Shares | 1↑0.3% | 1↑10.2% | 1↑106.4% | 0.60↑12.7% | 0.53 | |
| Weighted Average Diluted Shares | 1↑0.3% | 1↑10.2% | 1↑106.4% | 0.60↑12.7% | 0.53 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.